Trifunctional Compounds with Albumin-Binding for Stable Radionuclide Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current radiotherapeutic compounds face challenges in accumulating selectively in tumors while minimizing uptake in normal organs, and existing macrocyclic complexes with radionuclides are unstable, leading to non-selective targeting and toxicity.
Innovation Solution
Development of trifunctional compounds with an antigen-binding domain, a cytotoxin or imaging agent domain, and an albumin-binding moiety, which are more stable and target prostate-specific membrane antigen (PSMA), using macrocyclic complexes that are more stable with alpha-emitting radionuclides, allowing for effective tumor targeting with reduced toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional macrocyclic complexes with radionuclides are used, then radiotherapeutic activity is achieved, but stability is poor leading to non-selective targeting and toxicity
Solution Approach 1:
The patent employs a composite molecular structure comprising an antigen-binding domain (such as a diabody or scFv), a cytotoxin domain or imaging agent domain, and an albumin-binding moiety, all connected via linkers. This composite construct integrates multiple functional elements to achieve stable radionuclide complexation, selective tumor targeting through antigen binding, and reduced normal organ uptake through controlled pharmacokinetics, thereby resolving the contradiction between stability and toxicity
Solution Approach 2:
The radiotherapeutic agent is divided into distinct functional modules: an antigen-binding domain for selective targeting, a radionuclide-chelating domain for stable complexation, and an albumin-binding moiety for pharmacokinetic control. This segmentation allows each component to optimize its function independently while working together to achieve high stability and low toxicity
2Measurement precision
If traditional radiotherapeutic compounds are used, then tumor targeting is attempted, but selective accumulation in tumors is insufficient while normal organ uptake remains high
Solution Approach 1:
The patent applies local quality by endowing different parts of the molecule with specific functions: the antigen-binding domain provides high-affinity binding to PSMA on tumor cells, the radionuclide chelator ensures stable complexation to prevent release, and the albumin-binding moiety modulates plasma clearance to reduce kidney uptake. This localized functional differentiation enables precise tumor targeting while minimizing damage to normal organs
Solution Approach 2:
The albumin-binding moiety acts as an intermediary that modulates the pharmacokinetic behavior of the radiotherapeutic agent. By binding to albumin, the construct achieves extended circulation time and altered distribution patterns that favor tumor accumulation while reducing uptake in normal organs such as the kidney, thereby mediating between the targeting function and the clearance function
Data Source
AI summary
The present technology provides compounds, as well as compositions including such compounds, useful for imaging and/or treatment of a glioma, a breast cancer, an adrenal cortical cancer, a cervical carcinoma, a vulvar carcinoma, an endometrial carcinoma, a primary ovarian carcinoma, a metastatic ovarian carcinoma, a non-small cell lung cancer, a small cell lung cancer, a bladder cancer, a colon cancer, a primary, gastric adenocarcinoma, a primary colorectal adenocarcinoma, a renal cell carcinoma, and/or a prostate cancer. The compounds are represented by the following formulaor a pharmaceutically acceptable salt thereof.